

1 **Assessment of the use and quick preparation of saliva for rapid microbiological diagnosis of COVID-19.**

2 Mariana Fernández-Pittol*¹, Juan Carlos Hurtado*^{1,2}, Estela Moreno-García³, Elisa Rubio^{1,2}, Mireia
3 Navarro^{1,2}, Marta Valiente¹, Aida Peiró², Alicia Capón¹, Nuria Seijas⁴, Miguel J. Martínez^{1,2}, Climent
4 Casals-Pascual^{1,2}, Jordi Vila^{+1,2}.

5

6 ¹ Department of Clinical Microbiology, Hospital Clinic, University of Barcelona, Barcelona, Spain.

7 ² Institute of Global Health of Barcelona (ISGlobal), Barcelona, Spain.

8 ³ Department of Infectious Diseases, Hospital Clinic, University of Barcelona, Barcelona, Spain.

9 ⁴ Hospital at Home, Medical and Nurse Direction, Hospital Clinic, Barcelona, Spain

10 * Equal contribution to the study

11

12

13 ⁺ Corresponding author:

14 Jordi Vila; Department of Clinical Microbiology, Hospital Clinic, Villarroel, 170; 08036 Barcelona, Spain.

15 Tel. +34932275522; e-mail: jvila@clinic.cat

16

17 Running title: Use of heated saliva to detect SARS-CoV-2

18

19

20

21

22

23

24 **Abstract**

25 The objective of this study was to assess the performance of direct real time RT-PCR detection
26 of SARS-CoV-2 in heated saliva samples, avoiding the RNA isolation step. Oropharyngeal and
27 nasopharyngeal swabs together with saliva samples were obtained from 51 patients clinically
28 diagnosed as potentially having COVID-19. Two different methods were compared: 1. RNA was
29 extracted from 500 µl of sample using a MagNA Pure Compact Instrument with an elution
30 volume of 50µl and 2. 700µL of saliva were heat-inactivated at 96°C for 15 minutes, and directly
31 subjected to RT-PCR. One step real time RT-PCR was performed using 5 µl of extracted RNA or
32 directly from 5 µl of heated sample. RT-PCR was performed targeting the SARS-CoV-2 envelope
33 (E) gene region. Diagnostic performance was assessed using the results of the RT-PCR from
34 nasopharyngeal and oropharyngeal swabs as the gold standard. The overall sensitivity,
35 specificity, positive and negative predictive values were 81.08%, 92.86%, 96.77% and 65.00%,
36 respectively when RNA extraction was included in the protocol with saliva, whereas sensitivity,
37 specificity, positive and negative predictive values were 83.78%, 92.86%, 68.42% and 96.88%,
38 respectively, for the heat-inactivation protocol. However, when the analysis was performed
39 exclusively on saliva samples with a limited time from the onset of symptoms (<9 days, N=28),
40 these values were 90%, 87.5%, 44% and 98.75% for the heat-inactivation protocol. The study
41 showed that RT-PCR can be performed using saliva in an RNA extraction free protocol, showing
42 good sensitivity and specificity.

43

44 Keywords: RT-PCR, saliva, SARS-CoV-2, RNA extraction

45 **Introduction**

46 COVID-19 is a very devastating pandemic infection caused by SARS-CoV-2, which
47 originated in China and has currently spread all over the world¹. Rapid diagnosis of COVID-19 is
48 essential for the management of patients mainly in the emergency department². Although
49 some assays based on antigen-antibody reaction have been commercialized to detect either
50 antigens or antibodies (IgA, IgM or IgG), the most sensitive tool to detect SARS-CoV-2 continues
51 to be reverse-transcription real time polymerase chain reaction (RT-PCR) which specifically
52 amplifies different genes encoded in the viral RNA from nasopharyngeal and/oropharyngeal
53 swabs.

54 Shortages in swabs for collecting nasopharyngeal and oropharyngeal samples as well as
55 insufficient RNA extraction kits can lead to a critical situation during a pandemic in which a
56 huge number of samples must be processed. Therefore, the main objective of this study was to
57 evaluate the use of saliva as an alternative and easier-to-collect clinical sample to detect
58 COVID-19. The diagnostic performance of nasopharyngeal and oropharyngeal swabs was
59 compared to the performance of direct heated saliva to RNA extracted samples.

60

61 **Materials and methods**

62 *Patients*

63 Consecutive patients attending the Emergency Department at the Hospital Clinic of
64 Barcelona with laboratory or clinical-radiologic findings compatible with a diagnosis of COVID-
65 19 were included in the study. Patients presenting infections or lesions in the oropharyngeal
66 area were excluded. All patients included in the study had a primary diagnosis of COVID-19 by a

67 RT-PCR from oropharyngeal and nasopharyngeal swabs samples. Oropharyngeal and
68 nasopharyngeal swabs together with saliva samples were obtained from 51 patients clinically
69 diagnosed as potentially having COVID-19.

70 *Samples and procedure*

71 Nasopharyngeal and oropharyngeal swabs were deposited in a tube with 2 ml lysis
72 buffer (guanidine thiocyanate, 2M; sodium citrate pH 7.0, 30 mM; dithiothreitol, 2 mM and
73 triton X-100, 1%). All patients were asked to provide a saliva sample from the posterior
74 oropharynx before tooth brushing and meal intake. Patients were instructed and supervised by
75 a medical care team. Saliva samples with a volume less than 500µL were not included in the
76 study. The samples were transported to the Clinical Microbiology Department of the Hospital
77 Clinic in Barcelona, Spain, within less than 2 hours after collection. All saliva samples were
78 stored at -80°C and processed together.

79 Two different methods were compared. In the first method, 350 µL of saliva were mixed
80 with 350µL of lysis buffer (MagNA Pure Compact RNA Isolation Kit, Roche). RNA was extracted
81 from 500 µl of sample using a MagNA Pure Compact Instrument (Roche, Basel, Switzerland)
82 with an elution volume of 50µl. In the second method, 700µL of saliva were heat-inactivated at
83 96°C for 15 minutes, and 5 µl were subjected directly to RT-PCR. One step real time RT-PCR was
84 performed using the RNA Process Control Kit (Roche, Basel, Switzerland) with 5 µl of extracted
85 RNA or directly from 5 µl of heated sample. RT-PCR was performed targeting the SARS-CoV-2
86 envelope (E) gene region³. Diagnostic performance was assessed using the results of the RT-PCR
87 from nasopharyngeal and oropharyngeal swabs as the gold standard.

88

89 *Statistical analysis*

90 Statistical analyses were conducted using Stata 16.0 (*Iroc* and *Istat* functions) and
91 positive and negative-predictive (post-test) values were calculated for a disease prevalence of
92 10%.

93

94 **Results**

95 A total of 51 patients with suspicious of COVID-19 were included in the study
96 (Supplementary data 1), 37 patients gave positive by RT-PCR using oro- and naso-pharyngeal
97 swabs, whereas 14 were negative. The overall sensitivity, specificity, positive and negative
98 predictive values were 81.08%, 92.86%, 96.77% and 65.00%, respectively when RNA extraction
99 was included in the protocol with saliva, whereas sensitivity, specificity, positive and negative
100 predictive values were 83.78%, 92.86%, 68.42% and 96.88%, respectively, for the heat-
101 inactivation protocol (Supplementary data 2). However, when the analysis was performed
102 exclusively on saliva samples (heated only) with a limited time from the onset of symptoms (<9
103 days, N=28), these values were 90%, 87.5%, 44% and 98.75% for the heat-inactivation protocol
104 (Table).

105

106 **Discussion**

107 Two studies have recently evaluated the use of saliva for diagnosing SARS-CoV-2
108 infection, showing that the saliva viral load was highest during the first week after symptom

109 onset and subsequently declined over time, which suggests that saliva may be a good non-
110 invasive sample for detecting the presence of SARS-CoV-2 during the first days after the onset
111 of symptoms^{4,5}. Using RT-PCR, Pasomsu^{bet} *al.*⁶ found a sensitivity and specificity for saliva
112 samples of 84.2% [95% confidence interval (CI) 60.4%-96.6%], and 98.9% (95% CI 96.1%-99.9%),
113 respectively. Analysis of the two specimens demonstrated 97.5% of agreement (kappa
114 coefficient 0.851, 95% CI 0.723-0.979; $p < 0.001$). Moreover, it has also been suggested that
115 saliva could be a more sensitive alternative to nasopharyngeal swabs⁷. Our results are in
116 agreement with the abovementioned studies, but in addition we show that RT-PCR can be
117 performed using an RNA extraction-free protocol with 91.9% of concordance with
118 oropharyngeal and nasopharyngeal swabs (considering only samples collected below 9 days of
119 the onset of the symptoms) This protocol modification reduced the turnaround time by 40
120 minutes, taking into account the 10 minutes of pre-processing plus 30 minutes of RNA
121 extraction. In addition, the cost is also decreased. Moreover, the combination of a test with a
122 high negative predictive value, and the simplified logistics of sample collection (patients provide
123 the saliva samples with no need for personal protective equipment) is especially helpful to rule
124 out infection during times of low incidence and also in low-resource settings. Larger studies are
125 needed to prospectively validate these findings, and standardized saliva sample collection
126 protocols are also necessary prior to implementation in the clinical setting.

127

128 **References**

- 129 1.Chen J, Lu H, Melino G, et al. COVID-19 infection: the China and Italy perspectives. *Cell Death*
130 *Dis.* **2020**;11(6):438. Published 2020 Jun 8. doi:10.1038/s41419-020-2603-0
- 131 2.Loeffelholz MJ, Tang YW. Laboratory diagnosis of emerging human coronavirus infections -
132 the state of the art. *Emerg Microbes Infect.* **2020**;9(1):747-756. doi:10.1080/22221751.
133 2020.1745095.
- 134 3.Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, Bleicker T, Brunink S,
135 Schneider J, Schmidt ML, Mulders D, Haagmans BL, van der Veer B, van den Brink S, Wijsman L,
136 Goderski G, Romette JL, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C, Koopmans MPG,
137 Drosten C. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.*Euro Surveill*
138 **2020**; 25:2000045. doi:10.2807/1560-7917.ES.2020.25.3.2000045
- 139 4. To KK, Tsang OT, Chik-Yan Yip C, et al. Consistent detection of 2019 novel coronavirus in
140 saliva [published online ahead of print, 2020 Feb 12]. *Clin Infect Dis.* **2020**; ciaa149. doi: 10.1093
141 /cid/ciaa149
- 142 5. To KK, Tsang OT, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal
143 saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational
144 cohort study. *Lancet Infect Dis.* **2020**;20(5):565-574. doi:10.1016/S1473-3099(20)30196-1.
- 145 6. Pasomsub E, Watcharananan SP, Boonyawat K, et al. Saliva sample as a non-invasive
146 specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study [published
147 online ahead of print, 2020 May 15]. *Clin Microbiol Infect.* **2020**; S1198-743X(20)30278-0. doi:
148 10.1016/j.cmi. 2020.05.001

149

150 7. Wyllie AL, Fournier J, Casanovas-Massana A, et al. Saliva is more sensitive for SARS-CoV-2
151 detection in COVID-19 patients than nasopharyngeal swabs. medRxiv preprint. **2020**. Doi:
152 [https:// doi. org/10.1101/2020.04.16.20067835](https://doi.org/10.1101/2020.04.16.20067835).

Table. Sensitivity and specificity of RT-PCR in saliva sample using heat-inactivation protocol

Saliva (Heating only)	% (95%CI)	% (95%CI)
	all days (N=51)	<9 days (N=28)
Sensitivity	83.7 (67.9-93.8)	90.0 (68.3-98.7)
Specificity	92.8 (66.1-99.8)	87.5 (47.3-99.6)
Positive likelihood ratio	11.7 (1.76-77.9)	7.2 (1.14-45.3)
Negative likelihood ratio	0.17 (0.08-0.37)	0.11 (0.03-0.44)
Accuracy	91.9 (80.8-97.7)	87.7 (69.8-97)